Professor | Xingbing Wang | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Xingbing Wang
Contact Information	wangxingbing@ustc.edu.cn
Language ability	Chinese, English
Province	Anhui

Upload Avatar (500 x 500)

Name

Xingbing Wang

Contact Information

wangxingbing@ustc.edu.cn

Language ability

Chinese, English

Province

Anhui

University/Lab Affiliation and Title	University of Science and Technology of China
Faculty	Mayo Clinic College of Medicine
Academic Background & Achievements	2002-09 to 2005-06: PhD in Internal Medicine, Huazhong University of Science and Technology, Tongji Medical College Anhui Provincial Academic and Technical Leader Young Leading Talent in Anhui Health System
Work Experience	2005-07 to Present: Chief Physician, Deputy Director, Department of Hematology, The First Affiliated Hospital of USTC (Anhui Provincial Hospital) 2012-11 to 2012-12: Visiting Scholar, Oklahoma Medical Research Foundation, USA 2013-01 to 2013-09: Visiting Postdoctoral Fellow, Baylor Medical College, USA
Awards	Anhui Science and Technology Progress Award (2021): Second Prize 15th Anhui Youth Science and Technology Award (2013): Personal Award Anhui Science and Technology Progress Award (2015): Second Prize Anhui Science and Technology Progress Award (2011): Second Prize

University/Lab Affiliation and Title

University of Science and Technology of China

Faculty

Mayo Clinic College of Medicine

Academic Background & Achievements

2002-09 to 2005-06: PhD in Internal Medicine, Huazhong University of Science and Technology, Tongji Medical College
Anhui Provincial Academic and Technical Leader
Young Leading Talent in Anhui Health System

Work Experience

2005-07 to Present: Chief Physician, Deputy Director, Department of Hematology, The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
2012-11 to 2012-12: Visiting Scholar, Oklahoma Medical Research Foundation, USA
2013-01 to 2013-09: Visiting Postdoctoral Fellow, Baylor Medical College, USA

Awards

Anhui Science and Technology Progress Award (2021): Second Prize
15th Anhui Youth Science and Technology Award (2013): Personal Award
Anhui Science and Technology Progress Award (2015): Second Prize
Anhui Science and Technology Progress Award (2011): Second Prize

Areas of Focus	Basic and clinical translational research on immunotherapy for hematological tumors Research on chemotherapy and molecular targeted therapy for hematological tumors
Publications	Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies., Xu QW, Xu H, Xue L, Wang L, Zhang XH, Song KD, Yao W, Wan X, Tong J, Liu HL, Liu X, Zhu XY, Sun ZM, Wang XB, 2022 Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells., Xu Q, Xue L, An F, Xu H, Wang L, Geng L, Zhang X, Song K, Yao W, Wan X, Tong J, Liu H, Liu X, Zhu X, Zhai Z, Sun Z, Wang X, 2022 Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy., Xue L, Yi Y, Xu Q, Wang L, Yang X, Zhang Y, Hua X, Chai X, Yang J, Chen Y, Tao G, Hu B, Wang X, 2021 CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation., Xu QW, Xu H, Xue L, Wang M, Pan GW, Zhang XH, Song KD, Yao W, Wan X, Tong J, Liu HL, Xu HY, Liu X, Zhu XY, Sun ZM, Yang L, Wang XB, 2022 CD19 CAR-T细胞治疗复发难治Ph+急性B淋巴细胞白血病14例疗效及安全性., 何彩霞，薛磊，强萍，徐慧，张旭晗，刘欣，朱薇波，蔡晓燕，刘会兰，孙自敏，王兴兵, 2020 CAR-T细胞治疗混合表型急性白血病一例., 何彩霞，薛磊，翁良银，许倩文，朱薇波，刘欣，王兴兵, 2020 T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia., Xue L, Hu Y, Wang J, Liu X, Wang X, 2019 Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma., Sujun Li, Lei Xue, Min Wang, Ping Qiang, Hui Xu, Xuhan Zhang, Wenyao Kang, Fengtao You, Hanying Xu, Yu Wang, Xin Liu, Lin Yang, Xingbing Wang, 2019 Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy., Xu Q, Shi Y, Xue L, An F, Xu H, Liu X, Zhu X, Sun Z, Zhai Z, Wang X, 2023 Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell Malignancies., Wang Y, Sun R, Ge W, Xue L, Xu Q, Xu H, Li S, Wu M, Guo T, Wang X, 2023

Areas of Focus

Basic and clinical translational research on immunotherapy for hematological tumors
Research on chemotherapy and molecular targeted therapy for hematological tumors

Publications

Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies., Xu QW, Xu H, Xue L, Wang L, Zhang XH, Song KD, Yao W, Wan X, Tong J, Liu HL, Liu X, Zhu XY, Sun ZM, Wang XB, 2022
Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells., Xu Q, Xue L, An F, Xu H, Wang L, Geng L, Zhang X, Song K, Yao W, Wan X, Tong J, Liu H, Liu X, Zhu X, Zhai Z, Sun Z, Wang X, 2022
Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy., Xue L, Yi Y, Xu Q, Wang L, Yang X, Zhang Y, Hua X, Chai X, Yang J, Chen Y, Tao G, Hu B, Wang X, 2021
CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation., Xu QW, Xu H, Xue L, Wang M, Pan GW, Zhang XH, Song KD, Yao W, Wan X, Tong J, Liu HL, Xu HY, Liu X, Zhu XY, Sun ZM, Yang L, Wang XB, 2022
CD19 CAR-T细胞治疗复发难治Ph+急性B淋巴细胞白血病14例疗效及安全性., 何彩霞，薛磊，强萍，徐慧，张旭晗，刘欣，朱薇波，蔡晓燕，刘会兰，孙自敏，王兴兵, 2020
CAR-T细胞治疗混合表型急性白血病一例., 何彩霞，薛磊，翁良银，许倩文，朱薇波，刘欣，王兴兵, 2020
T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia., Xue L, Hu Y, Wang J, Liu X, Wang X, 2019
Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma., Sujun Li, Lei Xue, Min Wang, Ping Qiang, Hui Xu, Xuhan Zhang, Wenyao Kang, Fengtao You, Hanying Xu, Yu Wang, Xin Liu, Lin Yang, Xingbing Wang, 2019
Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy., Xu Q, Shi Y, Xue L, An F, Xu H, Liu X, Zhu X, Sun Z, Zhai Z, Wang X, 2023
Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell Malignancies., Wang Y, Sun R, Ge W, Xue L, Xu Q, Xu H, Li S, Wu M, Guo T, Wang X, 2023

Immunotherapy Hematological Tumors Clinical Research Translational Research Chemotherapy Molecular Therapy Targeted Therapy Cell Therapy Oncology Hematology

Fu-Sheng Wang - University of Science and Technology of China

Fei Wang - University of Science and Technology of China

Qun Sen - University of Science and Technology of China

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us